BRINGING YOU INFORMATION.  PROVIDING YOU A PLATFORM.

 

 
THE PHARMA REVIEW (SEPTEMBER - OCTOBER 2015)

Global Perspectives: Safety Worries of Indian Drugs - Is it Bound to Metastasize?

Dr. Ramalingam Peraman

Introduction: Indian drug manufacturing industry accounts for 22 % of global generic drugs and it is growing drastically. In purview of pharmacoeconomics, India supplies the cheapest drugs, with proper quality control measures. In fact, India being the second largest supplier of drugs, immediately after Canada, drugs manufactured by Indian generic companies has significant contribution on control of numerous life threatening diseases in public health. A recent report from United States (U.S) indicated that about 40% of generic and over-the-counter drugs used in their states, are being supplied by India. Approximately 80% of active pharmaceutical ingredients (so called APIís, nothing but bulk drug) available in United States for production of drug products (tablet, capsule, injections) are procured from out of the state. Nevertheless, the stable source of income for Indian generic industries from global market has significantly diminished. Instead, Indian generic companies are struggling to export their products and are searching a strategy to survive in the global market. Numerous news media stated that the reason for worsening situation is only due to the rise of spurious and substandard quality of generic drugs supplied by Indian industries. 

 

Go to Content Index Page

PHARMA REVIEW - ARTICLES ARCHIVE ( COMPLETE LIST)

 

The above content is an abstract only. For the full Article please contact:
KONGPOSH Publications Pvt. Ltd.
ICS House, C-19, Commercial Complex, SDA, Opp. IIT Gate, New Delhi, India -110016
Tel.: 26855839, 9811195411
Email: kongposhpub@gmail.com, Website: http://www.kppub.com

 
 
 
 

Copyright © KONGPOSH PUBLICATIONS Pvt. Ltd.